Significant Updates on Cellectis Share Capital
Cellectis is currently navigating through exciting timelines that focus on share capital and voting rights. As a prominent player in the gene editing industry, the company strives diligently to engage with its shareholders and keep them informed about the specifics of its capital structure.
Market Listing and Share Details
Recently, Cellectis reported its standing on the Euronext Growth market, which reflects its dedication to transparency and ongoing growth. The ISIN code for Cellectis, FR0010425595, is crucial for investors who track their share performance on various platforms.
Current Share and Voting Rights
As of the latest update, Cellectis holds a total of 100,093,873 shares. This figure is significant as it represents the breadth of the company's equity structure within the market. Notably, the total number of voting rights assigned to these shares stands at 88,660,571, indicating a robust engagement from shareholders in corporate decision-making processes.
Importance of Shareholder Engagement
Shareholder engagement plays a pivotal role in Cellectis's strategy. With a considerable number of voting rights, shareholders are equipped to influence key decisions affecting company direction, policies, and overall governance. This power is integral to the democratic process within the corporate structure and ensures that voices of investors are both heard and valued.
Who to Contact for More Information
For those interested in diving deeper into Cellectis's operations and updates, the company has made several key contacts available. Media inquiries can be directed to Pascalyne Wilson, the Director of Communications, who can be reached at +33 (0)7 76 99 14 33 or via email at media@cellectis.com.
Investor Relations for Cellectis
Investors looking to engage further with the financial aspects of Cellectis can contact Arthur Stril, the Interim Chief Financial Officer, at +1 (347) 809 5980 or send an email to investors@cellectis.com. These individuals are pivotal in helping stakeholders stay informed about financial health and business strategies.
Attachment Summary
For enhanced understanding, stakeholders can access the attached document detailed in Cellectis's latest update by following appropriate channels. This attachment provides further clarity on voting rights and related documentation.
Frequently Asked Questions
What is the significance of Cellectis’s share capital?
The share capital indicates the total equity structure of Cellectis, showcasing the number of shares available to investors and their voting capabilities.
How many shares does Cellectis currently have?
Cellectis has a total of 100,093,873 shares listed, reflecting its growth and operational scale.
What are voting rights in relation to shares?
Voting rights allow shareholders to vote on important company matters, ensuring they have a say in corporate governance and future direction.
Who manages investor relations at Cellectis?
Arthur Stril serves as the Interim Chief Financial Officer, managing investor relations and communication regarding financial matters.
Where can I find more information on Cellectis?
Interested parties can contact media and investor relations representatives directly or refer to the provided documentation for comprehensive details.
